Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine

Kidney Int. 2021 Aug;100(2):463-464. doi: 10.1016/j.kint.2021.05.007. Epub 2021 May 26.

Authors

Amy Holzworth¹, Patrick Couchot², Wanda Cruz-Knight², Michael Brucculeri³

Affiliations

¹ Section of Nephrology, Morton Plant Hospital, Clearwater, Florida, USA.
² Department of Family Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
³ Section of Nephrology, Morton Plant Hospital, Clearwater, Florida, USA; Department of Family Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA. Electronic address: Michael.Brucculeri@BAYCARE.ORG.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

2019-nCoV Vaccine mRNA-1273
COVID-19 Vaccines / adverse effects*
COVID-19* / prevention & control
Female
Humans
Middle Aged
Nephrosis, Lipoid* / chemically induced
Vaccines, Synthetic / adverse effects
mRNA Vaccines

Substances

COVID-19 Vaccines
Vaccines, Synthetic
2019-nCoV Vaccine mRNA-1273